Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Financials

CTNM Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 261.3 million 11.3 million
Dec. 31, 2025 276.6 million 15.7 million
Sept. 30, 2025 190.8 million 10.4 million
June 30, 2025 182.9 million 11.5 million

CTNM Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -16.6 million 3.8 million
Dec. 31, 2025 -13.1 million 2.5 million
Sept. 30, 2025 -12.3 million 2.6 million
June 30, 2025 -15.7 million 2.4 million

CTNM Net Income

No data available :(

CTNM Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 246.3 million 4.7 million 7.0 million
Dec. 31, 2025 262.9 million 5.9 million 8.3 million
Sept. 30, 2025 182.4 million 4.0 million 5.5 million
June 30, 2025 175.5 million - 5.8 million

CTNM Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 37.3 million
Dec. 31, 2025 30.9 million
Sept. 30, 2025 28.1 million
June 30, 2025 25.9 million

CTNM Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 312000 11.6 million 5.3 million -
Dec. 31, 2025 42000 12.8 million 4.4 million -
Sept. 30, 2025 98000 11.0 million 3.9 million -
June 30, 2025 44000 14.0 million 3.8 million -

CTNM Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 83000
Dec. 31, 2025 - 85000
Sept. 30, 2025 - 81000
June 30, 2025 - 79000

CTNM

Price: $12.42

52 week price:
3.57
16.33

Earnings Per Share: -1.94 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 429.6 million

Links: